Drug Profile

TRAILR2/CDH3 bispecific antibody - Boehringer Ingelheim pipeline, April 2025

Alternative Names: TR2/CDH3 BAB

Latest Information Update: 17 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cancer

Most Recent Events

24 Apr 2025 Phase-I clinical trials in Cancer (Parenteral) before April 2025 (Boehringer Ingelheim pipeline, April 2025)
09 Dec 2024 Preclinical trials in Cancer in Germany (Parenteral) before December 2024
09 Dec 2024 Pharmacodynamics and safety data from a preclinical trial in Cancer released by the Boehringer Ingelheim

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com